Mankind Pharma Limited — Others, 08-08-2025: Shareholders meeting

Mankind Pharma's 34th Annual General Meeting saw shareholders overwhelmingly approve all four resolutions. The adoption of the audited financial results for the financial year ended March 31, 2025, passed with nearly 100% approval. Shareholders also re-appointed Mr. Sheetal Arora as a Director (99.68% in favour), appointed Secretarial Auditors (99.84% in favour), and ratified Cost Auditor remuneration for FY 2025-26 (nearly 100% in favour). This strong mandate underscores investor support for the company's financial transparency, governance continuity, and key oversight functions.